<p>Stonebridge Financial Group LLC MO 在最近向证券交易委员会提交的 13F 文件中表示，在第四季度购买了 Eli Lilly and Company (NYSE:LLY - 免费报告) 的新股份。这家机构投资者购买了 1,397 股该公司的股票，价值约为 1,502,000 美元。Eli Lilly and Company 占 Stonebridge Financial Group LLC MO 持有的股份的 1.3%，使其成为该公司第 18 大持仓。</p>
<ul>
<li>FDA 最新提案对 Lilly、Novo 和 Hims 的影响</li>
</ul>
<p>其他一些大型投资者也增加或减少了对该股票的持股。10Elms LLP 在第三季度将其在 Eli Lilly and Company 的持股增加了 33.3%。10Elms LLP 现在拥有 40 股该公司的股票，价值 31,000 美元，在此期间又购买了 10 股。M.E. Allison &amp; CO. Inc. 在第四季度将其在 Eli Lilly and Company 的持股增加了 0.7%。M.E. Allison &amp; CO. Inc. 现在拥有 1,477 股该公司的股票，价值 1,587,000 美元，在此期间又购买了 10 股。Tanager Wealth Management LLP 在第四季度将其在 Eli Lilly and Company 的持股增加了 2.6%。Tanager Wealth Management LLP 现在拥有 395 股该公司的股票，价值 424,000 美元，在上个季度又购买了 10 股。Morey &amp; Quinn Wealth Partners LLC 在第四季度将其在 Eli Lilly and Company 的持股增加了 1.5%。Morey &amp; Quinn Wealth Partners LLC 现在拥有 661 股该公司的股票，价值 710,000 美元，在上个季度又购买了 10 股。最后，Wealthspan Partners LLC 在第四季度将其在 Eli Lilly and Company 的持股增加了 0.5%。Wealthspan Partners LLC 现在拥有 2,110 股该公司的股票，价值 2,268,000 美元，在此期间又购买了 10 股。对冲基金和其他机构投资者持有该公司 82.53% 的股票。</p>
<p>获取 <strong>Eli Lilly and Company</strong> 的提醒：</p>
<h2>影响 Eli Lilly and Company 的关键头条</h2>
<p>以下是本周影响 Eli Lilly and Company 的关键新闻：</p>
<ul>
<li>积极情绪：Lilly 的新三期肥胖数据表明 Foundayo 和低剂量 Zepbound 可以保持减重效果，增强了对其肥胖业务和未来增长的信心。Lilly 的 Foundayo 和低剂量 Zepbound 帮助人们在两项晚期试验中从高剂量注射类胰岛素疗法切换后维持减重。</li>
<li>积极情绪：报道强调 Lilly 的战略，计划通过下一代肥胖药物（包括口服药物和 retatrutide）超越 tirzepatide，可能会让投资者放心，认为公司正在保护其领导地位。Lilly 押注下一代肥胖药物以保持领先。</li>
<li>积极情绪：Omvoh 在溃疡性结肠炎的额外长期数据为 Lilly 的非肥胖管线提供了另一个证明点，并支持更广泛的增长故事。Eli Lilly 的 Omvoh 数据延续了溃疡性结肠炎的故事和估值吸引力。</li>
<li>中性情绪：Lilly 正在庆祝其 150 周年，推出各种公司、社区和领导人特写故事，但这些大多是声誉性的，单独来看不太可能对股价产生太大影响。Lilly CEO David Ricks 在公司庆祝历史的同时关注未来。</li>
<li>中性情绪：路透社报道 Lilly 在印度推出了其阿尔茨海默病药物，这是一个积极的商业发展，但由于市场关注肥胖增长，短期财务影响可能有限。Eli Lilly 在印度推出阿尔茨海默病药物 Donanemab。</li>
<li>消极情绪：竞争对手 GLP-1 开发者和新进入的肥胖药物公司（包括 Kailera Therapeutics）增加了竞争压力，表明 Lilly 的市场将保持高度竞争。这种减肥药物挑战者可能会遵循 Eli Lilly 的策略：分析师。</li>
<li>消极情绪：有报道称 Lilly 在印度暂停了一项肥胖意识活动，因监管通知可能会带来适度的阻力，尽管这似乎不是一个重大收益问题。Eli Lilly 在监管通知后暂停印度肥胖意识活动：报道。</li>
</ul>
<h2>Eli Lilly and Company 价格表现</h2>
<ul>
<li>Lilly 的双重超预期拉大了 GLP-1 的差距——而新药可能使其永久化</li>
</ul>
<p>NYSE LLY 的股票在周四开盘价为 1,014.93 美元。该公司的债务与股本比率为 1.26，速动比率为 1.10，流动比率为 1.50。Eli Lilly and Company 的 52 周低点为 623.78 美元，52 周高点为 1,133.95 美元。该公司的市值为 9558 亿美元，市盈率为 36.05，市盈增长比率为 1.08，贝塔值为 0.48。该股票的 50 日移动平均线为 939.87 美元，200 日移动平均线为 995.67 美元。</p>
<p>Eli Lilly and Company (NYSE:LLY - 获取免费报告) 最近在 4 月 30 日星期四发布了其财报。该公司报告本季度每股收益为 8.55 美元，超出市场共识预期的 6.97 美元，超出 1.58 美元。该业务在本季度的收入为 198 亿美元，而市场共识预期为 178.2 亿美元。Eli Lilly and Company 的股本回报率为 105.77%，净利润率为 34.98%。该公司的收入较去年同期增长了 55.5%。去年同期，该公司每股收益为 3.34 美元。Eli Lilly and Company 已将其 2026 财年的指导目标设定为 35.500-37.000 每股收益。股票研究分析师预计 Eli Lilly and Company 今年的每股收益将达到 35.8。</p>
<h2>Eli Lilly and Company 宣布分红</h2>
<ul>
<li>Viking Therapeutics 面临时间风险——但潜在收益可能巨大</li>
</ul>
<p>该公司还最近披露了一项季度分红，将于 6 月 10 日星期三支付。5 月 15 日的股东将获得 1.73 美元的分红。这相当于年化 6.92 美元的分红，分红收益率为 0.7%。除息日为 5 月 15 日。Eli Lilly and Company 的分红支付比率 (DPR) 为 24.58%。</p>
<h2>华尔街分析师预测增长</h2>
<p>多位分析师对 LLY 股票发布了报告。BMO 资本市场在 2 月 5 日的研究报告中重申了对礼来公司的 “跑赢大盘” 评级，并给出了 1,300.00 美元的目标价。大和证券集团在 2 月 18 日的研究报告中将礼来公司的目标价从 1,230.00 美元上调至 1,250.00 美元，并给予该公司 “买入” 评级。古根海姆在 5 月 5 日的报告中重申了 “买入” 评级，并设定了 1,183.00 美元的目标价。阿古斯在 2 月 9 日的研究报告中将礼来公司的目标价从 930.00 美元上调至 1,200.00 美元，并给予该股票 “买入” 评级。最后，自由资本在 2 月 10 日的研究报告中将礼来公司的评级从 “持有” 上调至 “强力买入”。两位分析师给予该股票 “强力买入” 评级，二十三位给予 “买入” 评级，四位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “适度买入”，共识目标价为 1,218.33 美元。</p>
<p><strong>查看我们最新的 LLY 股票分析</strong></p>
<h2>礼来公司公司简介</h2>
<p>（免费报告）</p>
<p>礼来公司 NYSE: LLY 是一家成立于 1876 年的全球制药公司，总部位于印第安纳州印第安纳波利斯。该公司研究、开发、生产和商业化广泛的药物和疗法，服务于全球患者。礼来在北美、欧洲、亚洲及其他地区开展业务并拥有商业存在，服务于发达市场和新兴市场。近年来，该公司由总裁兼首席执行官 David A.领导。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票超过礼来公司</li>
<li>D-Wave 的财报看起来疲软，但投资者可能忽视了这一点</li>
<li>随着 AI 反馈循环加剧，Nebius 的上行空间扩大</li>
<li>内部交易：Okta 和 Abbott 看到买入，Micron 内部人士卖出</li>
<li>Plug Power 开启盈利模式</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在礼来公司吗？</h2>
<p>在考虑礼来公司之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而礼来公司并不在名单上。</p>
<p>虽然礼来公司目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

礼来

2 倍做多 LLY ETF - Defiance

2 倍做多 LLY ETF - Direxion

<p>Stonebridge Financial Group LLC MO 在第四季度收购了 1,397 股礼来（NYSE: LLY），价值约 150 万美元，使其成为该投资组合中第 18 大持仓。其他投资者，包括 10Elms LLP 和 M.E. Allison & CO. Inc.，也调整了他们在礼来的股份。尽管面临竞争压力和监管挑战，该公司仍因其肥胖药物和近期发展而获得积极的市场情绪</p>

<p>Stonebridge Financial Group LLC MO purchased a new stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities &amp; Exchange Commission. The institutional investor purchased 1,397 shares of the company's stock, valued at approximately $1,502,000. Eli Lilly and Company accounts for 1.3% of Stonebridge Financial Group LLC MO's holdings, making the stock its 18th biggest position.</p>
<div class="lb-trans"><p>Stonebridge Financial Group LLC MO 在最近向证券交易委员会提交的 13F 文件中表示，在第四季度购买了 Eli Lilly and Company (NYSE:LLY - 免费报告) 的新股份。这家机构投资者购买了 1,397 股该公司的股票，价值约为 1,502,000 美元。Eli Lilly and Company 占 Stonebridge Financial Group LLC MO 持有的股份的 1.3%，使其成为该公司第 18 大持仓。</p>
</div><ul>
<li>What the FDA's Latest Proposal Means for Lilly, Novo, and Hims</li>
</ul>
<div class="lb-trans"><ul>
<li>FDA 最新提案对 Lilly、Novo 和 Hims 的影响</li>
</ul>
</div><p>A number of other large investors have also added to or reduced their stakes in the stock. 10Elms LLP grew its position in shares of Eli Lilly and Company by 33.3% during the 3rd quarter. 10Elms LLP now owns 40 shares of the company's stock valued at $31,000 after acquiring an additional 10 shares during the period. M.E. Allison &amp; CO. Inc. raised its holdings in shares of Eli Lilly and Company by 0.7% in the 4th quarter. M.E. Allison &amp; CO. Inc. now owns 1,477 shares of the company's stock worth $1,587,000 after purchasing an additional 10 shares during the period. Tanager Wealth Management LLP lifted its stake in Eli Lilly and Company by 2.6% in the fourth quarter. Tanager Wealth Management LLP now owns 395 shares of the company's stock valued at $424,000 after purchasing an additional 10 shares during the last quarter. Morey &amp; Quinn Wealth Partners LLC lifted its stake in Eli Lilly and Company by 1.5% in the fourth quarter. Morey &amp; Quinn Wealth Partners LLC now owns 661 shares of the company's stock valued at $710,000 after purchasing an additional 10 shares during the last quarter. Finally, Wealthspan Partners LLC grew its holdings in Eli Lilly and Company by 0.5% during the fourth quarter. Wealthspan Partners LLC now owns 2,110 shares of the company's stock valued at $2,268,000 after purchasing an additional 10 shares during the period. Hedge funds and other institutional investors own 82.53% of the company's stock.</p>
<div class="lb-trans"><p>其他一些大型投资者也增加或减少了对该股票的持股。10Elms LLP 在第三季度将其在 Eli Lilly and Company 的持股增加了 33.3%。10Elms LLP 现在拥有 40 股该公司的股票，价值 31,000 美元，在此期间又购买了 10 股。M.E. Allison &amp; CO. Inc. 在第四季度将其在 Eli Lilly and Company 的持股增加了 0.7%。M.E. Allison &amp; CO. Inc. 现在拥有 1,477 股该公司的股票，价值 1,587,000 美元，在此期间又购买了 10 股。Tanager Wealth Management LLP 在第四季度将其在 Eli Lilly and Company 的持股增加了 2.6%。Tanager Wealth Management LLP 现在拥有 395 股该公司的股票，价值 424,000 美元，在上个季度又购买了 10 股。Morey &amp; Quinn Wealth Partners LLC 在第四季度将其在 Eli Lilly and Company 的持股增加了 1.5%。Morey &amp; Quinn Wealth Partners LLC 现在拥有 661 股该公司的股票，价值 710,000 美元，在上个季度又购买了 10 股。最后，Wealthspan Partners LLC 在第四季度将其在 Eli Lilly and Company 的持股增加了 0.5%。Wealthspan Partners LLC 现在拥有 2,110 股该公司的股票，价值 2,268,000 美元，在此期间又购买了 10 股。对冲基金和其他机构投资者持有该公司 82.53% 的股票。</p>
</div><p>Get <strong>Eli Lilly and Company</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Eli Lilly and Company</strong> 的提醒：</p>
</div><h2>Key Headlines Impacting Eli Lilly and Company</h2>
<div class="lb-trans"><h2>影响 Eli Lilly and Company 的关键头条</h2>
</div><p>Here are the key news stories impacting Eli Lilly and Company this week:</p>
<div class="lb-trans"><p>以下是本周影响 Eli Lilly and Company 的关键新闻：</p>
</div><ul>
<li>Positive Sentiment: Lilly’s new phase 3 obesity data suggest Foundayo and lower-dose Zepbound can preserve weight-loss results, strengthening confidence in its obesity franchise and future growth. Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials</li>
<li>Positive Sentiment: Coverage highlighting Lilly’s strategy to expand beyond tirzepatide with next-generation obesity drugs, including an oral pill and retatrutide, may reassure investors that the company is protecting its leadership position. Lilly Bets on Next-Generation Obesity Drugs to Stay Ahead</li>
<li>Positive Sentiment: Additional long-term data for Omvoh in ulcerative colitis adds another proof point for Lilly’s non-obesity pipeline and supports the broader growth story. Eli Lilly’s Omvoh Data Extends Ulcerative Colitis Story And Valuation Appeal</li>
<li>Neutral Sentiment: Lilly is celebrating its 150th anniversary with various company, community, and leadership-profile stories, but these are mostly reputational and unlikely to move the stock much on their own. Lilly CEO David Ricks keeps eye on future while company celebrates history</li>
<li>Neutral Sentiment: Reuters reported Lilly launched its Alzheimer’s drug in India, a positive commercial development, but the immediate financial impact may be limited given the market’s focus on obesity growth. Eli Lilly launches Alzheimer's drug Donanemab in India</li>
<li>Negative Sentiment: Rival GLP-1 developers and new obesity entrants, including Kailera Therapeutics, add competitive pressure and show that Lilly’s market will remain highly contested. This Weight-Loss Drug Challenger Could Follow Eli Lilly's Playbook: Analyst</li>
<li>Negative Sentiment: Reports that Lilly paused an obesity awareness campaign in India after regulatory notices could be a modest headwind, though it does not appear to be a major earnings issue. Eli Lilly pauses Indian obesity awareness campaign after regulatory notices: report</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：Lilly 的新三期肥胖数据表明 Foundayo 和低剂量 Zepbound 可以保持减重效果，增强了对其肥胖业务和未来增长的信心。Lilly 的 Foundayo 和低剂量 Zepbound 帮助人们在两项晚期试验中从高剂量注射类胰岛素疗法切换后维持减重。</li>
<li>积极情绪：报道强调 Lilly 的战略，计划通过下一代肥胖药物（包括口服药物和 retatrutide）超越 tirzepatide，可能会让投资者放心，认为公司正在保护其领导地位。Lilly 押注下一代肥胖药物以保持领先。</li>
<li>积极情绪：Omvoh 在溃疡性结肠炎的额外长期数据为 Lilly 的非肥胖管线提供了另一个证明点，并支持更广泛的增长故事。Eli Lilly 的 Omvoh 数据延续了溃疡性结肠炎的故事和估值吸引力。</li>
<li>中性情绪：Lilly 正在庆祝其 150 周年，推出各种公司、社区和领导人特写故事，但这些大多是声誉性的，单独来看不太可能对股价产生太大影响。Lilly CEO David Ricks 在公司庆祝历史的同时关注未来。</li>
<li>中性情绪：路透社报道 Lilly 在印度推出了其阿尔茨海默病药物，这是一个积极的商业发展，但由于市场关注肥胖增长，短期财务影响可能有限。Eli Lilly 在印度推出阿尔茨海默病药物 Donanemab。</li>
<li>消极情绪：竞争对手 GLP-1 开发者和新进入的肥胖药物公司（包括 Kailera Therapeutics）增加了竞争压力，表明 Lilly 的市场将保持高度竞争。这种减肥药物挑战者可能会遵循 Eli Lilly 的策略：分析师。</li>
<li>消极情绪：有报道称 Lilly 在印度暂停了一项肥胖意识活动，因监管通知可能会带来适度的阻力，尽管这似乎不是一个重大收益问题。Eli Lilly 在监管通知后暂停印度肥胖意识活动：报道。</li>
</ul>
</div><h2>Eli Lilly and Company Price Performance</h2>
<div class="lb-trans"><h2>Eli Lilly and Company 价格表现</h2>
</div><ul>
<li>Lilly's Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It Permanent</li>
</ul>
<div class="lb-trans"><ul>
<li>Lilly 的双重超预期拉大了 GLP-1 的差距——而新药可能使其永久化</li>
</ul>
</div><p>Shares of NYSE LLY opened at $1,014.93 on Thursday. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,133.95. The stock has a market cap of $955.80 billion, a PE ratio of 36.05, a price-to-earnings-growth ratio of 1.08 and a beta of 0.48. The stock has a fifty day moving average of $939.87 and a 200-day moving average of $995.67.</p>
<div class="lb-trans"><p>NYSE LLY 的股票在周四开盘价为 1,014.93 美元。该公司的债务与股本比率为 1.26，速动比率为 1.10，流动比率为 1.50。Eli Lilly and Company 的 52 周低点为 623.78 美元，52 周高点为 1,133.95 美元。该公司的市值为 9558 亿美元，市盈率为 36.05，市盈增长比率为 1.08，贝塔值为 0.48。该股票的 50 日移动平均线为 939.87 美元，200 日移动平均线为 995.67 美元。</p>
</div><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping the consensus estimate of $6.97 by $1.58. The business had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The firm's revenue was up 55.5% compared to the same quarter last year. During the same quarter last year, the company earned $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities research analysts anticipate that Eli Lilly and Company will post 35.8 earnings per share for the current year.</p>
<div class="lb-trans"><p>Eli Lilly and Company (NYSE:LLY - 获取免费报告) 最近在 4 月 30 日星期四发布了其财报。该公司报告本季度每股收益为 8.55 美元，超出市场共识预期的 6.97 美元，超出 1.58 美元。该业务在本季度的收入为 198 亿美元，而市场共识预期为 178.2 亿美元。Eli Lilly and Company 的股本回报率为 105.77%，净利润率为 34.98%。该公司的收入较去年同期增长了 55.5%。去年同期，该公司每股收益为 3.34 美元。Eli Lilly and Company 已将其 2026 财年的指导目标设定为 35.500-37.000 每股收益。股票研究分析师预计 Eli Lilly and Company 今年的每股收益将达到 35.8。</p>
</div><h2>Eli Lilly and Company Announces Dividend</h2>
<div class="lb-trans"><h2>Eli Lilly and Company 宣布分红</h2>
</div><ul>
<li>Viking Therapeutics Faces Timeline Risk—But Upside Could Be Huge</li>
</ul>
<div class="lb-trans"><ul>
<li>Viking Therapeutics 面临时间风险——但潜在收益可能巨大</li>
</ul>
</div><p>The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date is Friday, May 15th. Eli Lilly and Company's dividend payout ratio (DPR) is 24.58%.</p>
<div class="lb-trans"><p>该公司还最近披露了一项季度分红，将于 6 月 10 日星期三支付。5 月 15 日的股东将获得 1.73 美元的分红。这相当于年化 6.92 美元的分红，分红收益率为 0.7%。除息日为 5 月 15 日。Eli Lilly and Company 的分红支付比率 (DPR) 为 24.58%。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Several analysts have issued reports on LLY shares. BMO Capital Markets restated an &#34;outperform&#34; rating and issued a $1,300.00 target price on shares of Eli Lilly and Company in a research note on Thursday, February 5th. Daiwa Securities Group boosted their price objective on Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the company a &#34;buy&#34; rating in a research note on Wednesday, February 18th. Guggenheim reaffirmed a &#34;buy&#34; rating and set a $1,183.00 price objective on shares of Eli Lilly and Company in a report on Tuesday, May 5th. Argus increased their target price on shares of Eli Lilly and Company from $930.00 to $1,200.00 and gave the stock a &#34;buy&#34; rating in a research report on Monday, February 9th. Finally, Freedom Capital upgraded shares of Eli Lilly and Company from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research note on Tuesday, February 10th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $1,218.33.</p>
<div class="lb-trans"><p>多位分析师对 LLY 股票发布了报告。BMO 资本市场在 2 月 5 日的研究报告中重申了对礼来公司的 “跑赢大盘” 评级，并给出了 1,300.00 美元的目标价。大和证券集团在 2 月 18 日的研究报告中将礼来公司的目标价从 1,230.00 美元上调至 1,250.00 美元，并给予该公司 “买入” 评级。古根海姆在 5 月 5 日的报告中重申了 “买入” 评级，并设定了 1,183.00 美元的目标价。阿古斯在 2 月 9 日的研究报告中将礼来公司的目标价从 930.00 美元上调至 1,200.00 美元，并给予该股票 “买入” 评级。最后，自由资本在 2 月 10 日的研究报告中将礼来公司的评级从 “持有” 上调至 “强力买入”。两位分析师给予该股票 “强力买入” 评级，二十三位给予 “买入” 评级，四位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “适度买入”，共识目标价为 1,218.33 美元。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on LLY</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 LLY 股票分析</strong></p>
</div><h2>Eli Lilly and Company Company Profile</h2>
<div class="lb-trans"><h2>礼来公司公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.</p>
<div class="lb-trans"><p>礼来公司 NYSE: LLY 是一家成立于 1876 年的全球制药公司，总部位于印第安纳州印第安纳波利斯。该公司研究、开发、生产和商业化广泛的药物和疗法，服务于全球患者。礼来在北美、欧洲、亚洲及其他地区开展业务并拥有商业存在，服务于发达市场和新兴市场。近年来，该公司由总裁兼首席执行官 David A.领导。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Eli Lilly and Company</li>
<li>D-Wave Earnings Looked Weak, But Investors May Be Missing This</li>
<li>Nebius Upside Expands as AI Feedback Loop Intensifies</li>
<li>Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell</li>
<li>Plug Power Flips The Switch On Profitability</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过礼来公司</li>
<li>D-Wave 的财报看起来疲软，但投资者可能忽视了这一点</li>
<li>随着 AI 反馈循环加剧，Nebius 的上行空间扩大</li>
<li>内部交易：Okta 和 Abbott 看到买入，Micron 内部人士卖出</li>
<li>Plug Power 开启盈利模式</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=LLY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在礼来公司吗？</h2>
</div><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑礼来公司之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而礼来公司并不在名单上。</p>
</div><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然礼来公司目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Stonebridge Financial Group LLC MO 购入了礼来公司（Eli Lilly and Company）1,397 股股票